Novel Schizophrenia Treatments Target Glutamate Receptors
the Psychiatry Advisor take:
Antagonism or partial agonism at the dopamine D2 receptor and antagonism at the serotonin 5-HT2A receptor are what most schizophrenia drugs target in the brain. While these medications have been effective, other drugs are typically added to a treatment regimen to deal with negative symptoms or cognitive impairment.
However, new agents are in development for the treatment of schizophrenia. As Leslie Citrome, MD, of the Department of Psychiatry and Behavioral Sciences, New York Medical College, in Valhalla, says, many new treatment on the horizon involve the neurotransmitter glutamate.
Activating glutamate can produce either an increase or decrease in the release of dopamine in the brain, which in turn impacts areas related to the symptoms of schizophrenia.
While both metabotropic and ionotropic glutamate receptors have been researched, Citrome said in Psyclopedia that most schizophrenia drugs under development target MNDA receptors, which have seen positive results in trials.
He also describes a non-glutamate treatment, encenicline (EVP-6124), which is a selective α7 nicotinic acetylcholine (N-A7A) receptor agonist. These receptors are located in brain areas involved in cognitive functions.
“Effective treatments for negative and cognitive symptoms remain an unmet need in schizophrenia management,” Citrome concludes. “Strategies such as combining antipsychotics and adding adjunctive agents to antipsychotics have yielded mostly disappointing results for both of these symptom domains.
“The NMDA receptor hypofunction hypothesis, with its focus on the glutamate system’s effect on dopamine, may potentially explain the positive, negative, and cognitive symptoms of schizophrenia. Therapeutic targets different from those of current antipsychotic agents are actively being investigated. Research includes adjunctive agents that bind to sites on NMDA receptors (glycine, d-serine, d-cycloserine), adjunctive glycine reuptake inhibitors (sarcosine, bitopertin), as well as agents that work through different pathways (encenicline).”
New Drugs in Development to Treat Schizophrenia
Psychiatry Advisor Articles
- Early Detection Markers of Alzheimer's Disease Possibly Identified
- Transcranial Direct Current Stimulation Inferior to Escitalopram
- Illicit Cannabis Use Among Adults Up Due to Medical Marijuana Laws
- Memory Training Opportunities Exist for Patients With Schizophrenia
- APA: Medical Discrimination Based on Size Psychologically, Physically Harms Patients
- Criteria For Identification of Smartphone Addiction
- Bipolar Disorder: Childhood Trauma Modulates Impact on Amygdala, Hippocampus
- Psychiatric Evaluations: Questions on Suicide Need to Be Rephrased
- Subsequent Suicide Attempts May Be Reduced by Emergency Department Interventions
- Elevated Levels of Childhood Adversity in Patients with Fibromyalgia and Chronic Widespread Pain
- Prescription Opioid Misuse Remains a Persistent Problem
- Revised Treatment Guidelines for Pediatric Acute Onset Neuropsychiatric Syndrome
- Long-term Response to Prophylactic Mood Stabilizers in Bipolar Disorder
- Medically Supervised Withdrawal, an Option for Pregnant Women Addicted to Opioids
- Navigating the Thin Line Between Identification & Intimacy With Patients